TegoScience Inc. (KOSDAQ:191420)
South Korea · Delayed Price · Currency is KRW 15,040
+40 (0.27%)
At close: Jan 28, 2026
TegoScience Revenue
TegoScience had revenue of 1.62B KRW in the quarter ending September 30, 2025, a decrease of -18.26%. This brings the company's revenue in the last twelve months to 6.15B, down -11.15% year-over-year. In the year 2024, TegoScience had annual revenue of 6.76B, down -13.04%.
Revenue (ttm)
6.15B
Revenue Growth
-11.15%
P/S Ratio
19.25
Revenue / Employee
n/a
Employees
n/a
Market Cap
118.50B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 6.76B | -1.01B | -13.04% |
| Dec 31, 2023 | 7.77B | 94.02M | 1.22% |
| Dec 31, 2022 | 7.68B | -621.23M | -7.49% |
| Dec 31, 2021 | 8.30B | -489.49M | -5.57% |
| Dec 31, 2020 | 8.79B | 2.44B | 38.50% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CTCBIO | 132.76B |
| KoBioLabs | 71.83B |
| Cell Biotech | 50.65B |
| Choong Ang Vaccine Laboratory | 39.19B |
| Naturalendo Tech | 21.87B |
| BIO-FD&C | 18.82B |
| NovMetaPharma | 1.30B |
| Progen | 450.00M |